A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)

A Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA Nephropathy at Risk of Progressing to End-Stage Renal Disease (NefIgArd)
Recruiting
1 years - 100 years
All
Phase 3
1 Location

Brief description of study

    The research study is being conducted to see how well the investigational drug, Nefecon, works for the treatment of your kidney disease and more specific for patients with "primary immunoglobulin A nephropathy," called IgAN.

    Eligibility of study

    You may be eligible for this study if you meet the following criteria:

    • Conditions: IgAN,primary immunoglobulin A nephropathy
    • Age: 1 years - 100 years
    • Gender: All


    Updated on 19 Feb 2024. Study ID: 833614

    Find a site

    Message sent successfully.
    We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
    If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
    Sign up

    Send a message

    Enter your contact details to connect with study team

    Email

    View email

    Phone

    Phone country flag

    View phone
    Investigator Avatar

    Primary Contact

    First name*
    Last name*
    Email*
    Phone number*
    Preferred way of contact
    Race
    Ethnicity
    Other language

    Message For Non Enrolling By Invitation Trial

    Select a study center that’s convenient for you, and get in touch with the study team.